c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a protein that in humans is encoded by the KIT gene. c-Kit (CD117) is an important cell surface marker used to identify certain types of hematopoietic (blood) progenitors in the bone marrow. c-Kit is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. c-Kit is a receptor tyrosine kinase type III, which binds to stem cell factor. When c-Kit binds to stem cell factor (SCF) it forms a dimer that activates its intrinsic tyrosine kinase activity, that in turn phosphorylates and activates signal transduction molecules that propagate the signal in the cell. Signalling through c-Kit plays a role in cell survival, proliferation, and differentiation.
<table>
<thead>
<tr>
<th><strong>c-Kit Inhibitors</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AC710</strong></td>
<td><strong>Amuvatinib</strong> (MP470; HPK 56)</td>
</tr>
<tr>
<td>Cat. No.: HY-13493</td>
<td>Cat. No.: HY-10206</td>
</tr>
<tr>
<td>AC710 is a potent PDGFR inhibitor with (K_{i})s of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.</td>
<td>Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, FLT3, c-Met and c-Ret.</td>
</tr>
<tr>
<td>Purity: 98.03%</td>
<td>Purity: 99.36%</td>
</tr>
<tr>
<td>Clinical Data: No Development Reported</td>
<td>Clinical Data: Phase 2</td>
</tr>
<tr>
<td>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td>Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

| **Amuvatinib hydrochloride** (MP470 hydrochloride; HPK 56 hydrochloride) | **AST 487** (NVP-AST 487) |
| Cat. No.: HY-10206A | Cat. No.: HY-15002 |
| Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, FLT3, c-Met and c-Ret. | AST 487 is a RET kinase inhibitor with \(I_{50}\) of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits FLT-3 with \(I_{50}\) of 520 nM. |
| Purity: >98% | Purity: 99.20% |
| Clinical Data: No Development Reported | Clinical Data: No Development Reported |
| Size: 1 mg, 5 mg | Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg |

| **Avapritinib** (BLU-285) | **AZD2932** |
| Cat. No.: HY-101561 | Cat. No.: HY-18179 |
| Avapritinib (BLU-285) is a highly potent, selective, and orally active KIT and PDGFRα activation loop mutant kinases inhibitor with \(I_{50}\)s of 0.27 and 0.24 nM for KIT D816V and PDGFRα D842V, respectively. | AZD2932 is a potent and multi-targeted kinase inhibitor VEGFR2, PDGFRα, FLT-3 and c-Kit with \(I_{50}\)s of 8, 4, 7 and 9 nM in cell assay, respectively. |
| Purity: 99.94% | Purity: 98.12% |
| Clinical Data: Launched | Clinical Data: No Development Reported |
| Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |

| **AZD3229** | **AZD3229 Tosylate** |
| Cat. No.: HY-112802 | Cat. No.: HY-112802A |
| AZD3229 is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. | AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. |
| Purity: 99.55% | Purity: 98.54% |
| Clinical Data: No Development Reported | Clinical Data: No Development Reported |
| Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg | Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg |

| **c-Kit-IN-1** | **c-Kit-IN-2** |
| Cat. No.: HY-15240 | Cat. No.: HY-128602 |
| c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with \(I_{50}\)s of <200 nM. | c-Kit-IN-2 is a c-KIT inhibitor with an \(I_{50}\) of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GST882, GST430, and GST48, with \(I_{50}\)s of 3, 1, and 2 nM, respectively. |
| Purity: 98.46% | Purity: >98% |
| Clinical Data: Phase 1 | Clinical Data: No Development Reported |
| Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg | Size: 1 mg, 5 mg |
c-Kit-IN-3

**Cat. No.:** HY-128704

**Purity:** 99.07%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

**c-Kit-IN-3 hydrochloride**

**Cat. No.:** HY-128704A1

**Purity:** 99.98%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

**c-Kit-IN-3 maleate**

**Cat. No.:** HY-128704A4

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg

**Cabozantinib**

**(XL184, BMS-97351)**

**Cat. No.:** HY-13016

**Purity:** 99.85%

**Clinical Data:** Launched

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

**CHMFL-ABL/KIT-155**

**(CHMFL-ABL-KIT-155)**

**Cat. No.:** HY-101034

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg

**c-Kit-IN-3 D-tartrate**

**Cat. No.:** HY-128704A5

**Purity:** 99.97%

**Clinical Data:** No Development Reported

**Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

**c-Kit-IN-3 L-tartrate**

**Cat. No.:** HY-128704A6

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg

**DCC-3014**

**Cat. No.:** HY-136256

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 5 mg, 10 mg, 25 mg, 50 mg, 100 mg
Dovitinib (TKI258; CHR-258)  
Cat. No.: HY-50905

Dovitinib (TKI258; CHR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRαβ, respectively.

Purity: 97.18%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Flumatinib mesylate (HHGV678 mesylate)  
Cat. No.: HY-13905

Flumatinib mesylate (HH-GV-678 mesylate), a derivative of imatinib, is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively.

Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 50 mg

Imatinib (STI571; CGP-57148B)  
Cat. No.: HY-15463

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.

Purity: 99.80%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib D8 (STI571 D8; CGP-57148B D8)  
Cat. No.: HY-154635

Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

ISCK03  
Cat. No.: HY-101443

ISCK03 is a specific SCF/c-Kit inhibitor.

Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Flumatinib (HHGV678)  
Cat. No.: HY-13904

Flumatinib (HHGV678) is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively.

Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

HG-7-85-01  
Cat. No.: HY-15814

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib D4 (STI571 D4; CGP-57148B D4)  
Cat. No.: HY-1546351

Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib Mesylate (STI571 Mesylate; CGP-57148B Mesylate)  
Cat. No.: HY-50946

Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC₅₀=100 nM) tyrosine kinases.

Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 200 mg, 500 mg, 1 g, 5 g

Ki20227  
Cat. No.: HY-10408

Ki20227 is an orally active and highly selective c-fms tyrosine kinase (CSF1R) inhibitor with IC₅₀ of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor...
Lenatinib (E7080)
Cat. No.: HY-10981
Lenatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.

Purity: 99.74%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Linifanib
Cat. No.: HY-50751
Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC_{50} of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFR β, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity.

Purity: 99.60%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib mesylate
Cat. No.: HY-10209A
Masitinib mesylate (AB-1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC_{50}=540/800 nM), Lyn (IC_{50}=510 nM for LynB), Lck, and, to a lesser extent, FGRF3 and FAK.

Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Motesanib
Cat. No.: HY-10228
Motesanib is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC_{50} of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret. It also inhibits PDGFRα/β, c-Kit, and Bcr-abl.

Purity: 99.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OSI-930
Cat. No.: HY-10204
OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC_{50} of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl.

Purity: 97.23%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pazopanib
Cat. No.: HY-10208
Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
</table>
| **Pazopanib Hydrochloride** (GW786034 Hydrochloride) | HY-12009 | is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-fms with an IC\textsubscript{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.  

Purity: 99.83%  
Clinical Data: Launched  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg |
| **Pexidartinib hydrochloride** (PLX-3397 hydrochloride) | HY-16749A | is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC\textsubscript{50}s of 20 and 10 nM, respectively.  

Purity: 99.64%  
Clinical Data: Launched  
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg |
| **Pexidartinib** (PLX-3397) | HY-16749 | is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC\textsubscript{50}s of 20 and 10 nM, respectively.  

Purity: 99.64%  
Clinical Data: Launched  
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg |
| **PLX647** | HY-13838 | is a highly specific dual FMS/KIT kinase inhibitor with IC\textsubscript{50} of 28/16 nM respectively.  

Purity: 98.20%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |
| **Ripretinib** (DCC-2618) | HY-112306 | is an orally bioavailable, selective KIT and PDGFR\textalpha{} switch-control inhibitor.  

Purity: 99.46%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg |
| **Sitravatinib** (MGCD516; MG-516) | HY-16961 | is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC\textsubscript{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.  

Purity: >98%  
Clinical Data: Phase 2  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg |
| **SU14813** | HY-10501 | is a multi-targeted receptor tyrosine kinases inhibitor with IC\textsubscript{50}s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFR\textbeta{} and KIT.  

Purity: 98.90%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg |
| **SU14813 maleate** | HY-10501A | is a multi-targeted receptor tyrosine kinases inhibitor with IC\textsubscript{50}s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFR\textbeta{} and KIT.  

Purity: 99.95%  
Clinical Data: No Development Reported  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg |
| **Tandutinib** (MLN518; CT3518) | HY-10202 | is a potent and selective inhibitor of the FLT3 with an IC\textsubscript{50} of 0.22 μM, and also inhibits c-Kit and PDGFR with IC\textsubscript{50}s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML).  

Purity: 99.48%  
Clinical Data: Phase 2  
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg |
<table>
<thead>
<tr>
<th>Chemical Name</th>
<th>CAS Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tandutinib hydrochloride (MLN518 hydrochloride; CT53518 hydrochloride)</td>
<td>HY-10202A</td>
<td>Potent and selective inhibitor of the FLT3 with an IC₅₀ of 0.22 μM, and also inhibits c-Kit and PDGFR with IC₅₀ of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML).</td>
</tr>
<tr>
<td>Telatinib (Bay 57-9352)</td>
<td>HY-10527</td>
<td>Orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGFRα, and c-Kit with IC₅₀ of 6, 4, 15 and 1 nM, respectively.</td>
</tr>
<tr>
<td>Telatinib mesylate (Bay 57-9352 mesylate)</td>
<td>HY-10527C</td>
<td>Potent and orally active VEGFR2, VEGFR3, PDGFα, and c-Kit inhibitor with IC₅₀ of 6 nM, 4 nM, 15 nM and 1 nM, respectively.</td>
</tr>
<tr>
<td>Toceranib phosphate (SU11654 phosphate; PHA 291639E phosphate)</td>
<td>HY-10330A</td>
<td>Orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFRβ, VEGFR, and Kit with Kᵦ of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.</td>
</tr>
</tbody>
</table>

**Purity:**
- Tandutinib hydrochloride: 98.84%
- Telatinib: 99.49%
- Telatinib mesylate: >98%
- Toceranib phosphate: 98.43%

**Clinical Data:**
- Tandutinib hydrochloride: Phase 2
- Telatinib: Phase 2
- Telatinib mesylate: No Development Reported
- Toceranib phosphate: Launched

**Size:**
- Tandutinib hydrochloride: 10 mM × 1 mL, 50 mg, 100 mg
- Telatinib: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
- Telatinib mesylate: 1 mg, 5 mg
- Toceranib phosphate: 10 mg, 50 mg